EMA advises malaria drugs use for trials only; FDA records shortage
The European Medicines Agency (EMA) has urged that two malaria drugs, chloroquine and hydroxychloroquine, being tested as potential Covid-19 treatment, must only be used for clinical trials or national emergency use programmes.
Separately, the US Food and Drug Administration (FDA) said that these drugs are in shortage due to increased demand amid the Covid-19 pandemic.